While cannabis gel stocks fall, biopharma companies rise to the challenge

Zynerba Pharmaceuticals Inc. reported a failed clinical trial for cannabidiol gel in adult epilepsy, which caused its stock to plummet 58.5 percent this week.

The Zynerba trial found that ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period.

Armando Anido, chief executive officer of Zynerba, said: “We are very disappointed that the STAR 1 trial did not meet its primary endpoint in this patient population. We are continuing to evaluate this study and the ongoing STAR 2 open label study to determine next steps with ZYN002 in adult epilepsy patients with focal seizures.”

Zynerba uses synthetic CBD for STAR 1 instead of the botanical plant based compound. With two products on the market, the company’s stocks took a hit as a result of the failed trial.

While Zynerba’s clinical trial didn’t perform as they’d hoped, other companies are seeing success in developing cannabinoid medications,

... read more at: https://www.cashinbis.com/cannabis-gel-stocks-fall-biopharma-companies-rise-challenge/


Leave a Reply

Your email address will not be published. Required fields are marked *